O T C
PAOG Target CBD Pharma Development In Puerto Rico Could Get Boost From COVID-19

Sandusky, OH – Sep 17, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today highlighted recent increased interest in the resurgence of industry-wide Pharmaceutical research and manufacturing in Puerto Rico. PAOG is currently in discussions in to engage a Contract Research Organization (CRO) in Puerto Rico to advance an Investigational New

PAOG Announces Agreement To Build Pharmaceutical Hemp Cultivar Facility On PURA Farmersville Site

Sandusky, OH – September 16, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced an agreement with Puration, Inc. (OTC PINK: PURA) to build a proprietary hemp cultivar development facility on PURA’s Farmersville, Texas branded site.    PAOG recently acquired a hemp cultivation business from PURA and is now expanding

PAOG Advances RespRx Research Into International CBD Pharma Research Arena

Sandusky, OH – Sep 15, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced an international research initiative to advance its hemp-derived cannabidiol (CBD) pharmaceutical treatment for Chronic Obstructive Pulmonary Disease (COPD). The COPD treatment, RespRx, is derived from a patented cannabis extraction method – U.S. Patent No. 9,199,960 entitled

PAOG Goes Global With CBD Pharmaceutical Research To Target $5.8 Billion Market

Sandusky, OH – Sep 15, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) Announces a multifold, international research initiative to advance its hemp-derived cannabidiol (CBD) pharmaceutical treatment for Chronic Obstructive Pulmonary Disease (COPD). The COPD treatment, RespRx, is derived from a patented cannabis extraction method – U.S. Patent No. 9,199,960 entitled

PAOG Completes Compliance Updates In Conjunction With Cannabis Biopharma Revitalization Initiative

Sandusky, OH – August 27, 2020 –  OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced having published all required filings necessary to meet the OTC Markets “Current Information” reporting standard. Yesterday, the company published the final compliance requirement, a legal opinion, following the publications of its Q1 2020 and Q2 2020

Immune Therapeutics, Inc. Announces Advisory Board Appointments

  ORLANDO, Fla., October 22, 2019 — OTC PR WIRE — Immune Therapeutics, Inc. (OTCQB: IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS announced today that Dr. Robert Buckheit, Jr. will join the Scientific Advisory

Contact Us

  • 707-OTC-WIRE (707-682-9473)
  • cs@otcprwire.com

All Rights Reserved © 2019